Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 411

1.

Pathologic and clinical features of 77 Hodgkin's lymphoma patients treated in a lymphoma protocol (LNH87): a GELA study.

Cazals-Hatem D, André M, Mounier N, Copin MC, Divine M, Berger F, Bosly A, Kerneis Y, Brière J, Quesnel B, Diebold J, Gaulard P.

Am J Surg Pathol. 2001 Mar;25(3):297-306.

PMID:
11224599
2.

[Efficacy of therapy of different variants of anaplastic large T-cell lymphomas].

Vinogradova IuE, Lutsenko IN, Kaplanskaia IB, Vorob'ev IA, Samoĭlova RS, Gorgidze LA, Ryzhikova NA, Valiev TT, Giliazitdinova EA, Dzhulakian UL, Egorova EK, Zvonkov EE, Krasil'nikova BB, Magomedova AU, Margolin OV, Mar'in DS, Kremenetskaia AM, Kravchenko SK, Vorob'ev AI.

Ter Arkh. 2008;80(7):33-7. Russian.

PMID:
18763592
3.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
4.

Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA).

Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J, Reyas F, Gaulard P.

Blood. 1996 Jan 1;87(1):265-72.

5.

Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma.

Willenbrock K, Küppers R, Renné C, Brune V, Eckerle S, Weidmann E, Bräuninger A, Hansmann ML.

Haematologica. 2006 May;91(5):596-604.

6.

Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.

Escalón MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL, Dang NH.

Cancer. 2005 May 15;103(10):2091-8.

7.

[Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].

Zou GR, Zhang YJ, Xie FY, Zheng W, Li HX, Xia YF, Lin TY, Lu TX.

Ai Zheng. 2006 Dec;25(12):1543-9. Chinese.

PMID:
17166383
8.

Value of fine-needle aspiration cytology in diagnosis of Hodgkin's lymphoma and anaplastic large cell lymphoma: one centre experience.

Kolonić SO, Prasek-Kudrna K, Roso V, Radić-Kristo D, Planinc-Peraica A, Dzebro S, Kardum-Skelin I, Jaksić B.

Coll Antropol. 2010 Mar;34(1):75-9.

PMID:
20432736
9.

[Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].

Fu XH, Wang SS, Huang Y, Wang B, Huang HQ, Zhang L, Sun XF, Xu RH, Lin TY.

Ai Zheng. 2006 Aug;25(8):1013-8. Chinese.

PMID:
16965685
10.

Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.

Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, Schmitz T, Wildt L, Diehl V, Engert A; German Hodgkin's Lymphoma Study Group.

J Clin Oncol. 2005 Oct 20;23(30):7555-64.

PMID:
16234521
11.

[Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].

Qin Y, Shi YK, He XH, Yang JL, Yang S, Yu YX, Li B, Wang QL, Zhou LQ, Sun Y.

Ai Zheng. 2006 Apr;25(4):481-5. Chinese.

PMID:
16613685
12.

Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients.

André M, Mounier N, Leleu X, Sonet A, Brice P, Henry-Amar M, Tilly H, Coiffier B, Bosly A, Morel P, Haioun C, Gaulard P, Reyes F, Gisselbrecht C; Groupe D'Etude Des Lymphomes De L'Adulte.

Blood. 2004 Feb 15;103(4):1222-8. Epub 2003 Oct 23.

13.
14.

Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA).

Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Brière J, Haioun C, Cazals-Hatem D, Bosly A, Xerri L, Tilly H, Berger F, Bouhabdallah R, Diebold J.

Blood. 1998 Jul 1;92(1):76-82.

15.

CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis.

Gorczyca W, Tsang P, Liu Z, Wu CD, Dong HY, Goldstein M, Cohen P, Gangi M, Weisberger J.

Int J Oncol. 2003 Feb;22(2):319-24.

PMID:
12527929
16.

[Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].

Tan WY, Hu DS, Zeng FY, Song QB, Hu S, Wei L, Zhou LQ.

Ai Zheng. 2007 Dec;26(12):1360-4. Chinese.

PMID:
18076802
17.

Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma.

Niitsu N, Okamoto M, Tomita N, Aoki S, Tamaru J, Miura I, Hirano M.

Leuk Lymphoma. 2006 Sep;47(9):1908-14.

PMID:
17065005
18.
19.
20.

CD30 (Ki-1)-positive malignant lymphomas: clinical, immunophenotypic, histologic, and genetic characteristics and differences with Hodgkin's disease.

Filippa DA, Ladanyi M, Wollner N, Straus DJ, O'Brien JP, Portlock C, Gangi M, Sun M.

Blood. 1996 Apr 1;87(7):2905-17.

Supplemental Content

Support Center